BioArctic AB
Clinical trials sponsored by BioArctic AB, explained in plain language.
Swedish biopharmaceutical company developing treatments for neurodegenerative diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New drug trial aims to tame Parkinson's and MSA
Disease control CompletedThis study tests a new medicine called exidavnemab in people with mild to moderate Parkinson's disease or multiple system atrophy. The main goal is to check if the drug is safe and how the body processes it. Participants will receive either the drug or a placebo, and researchers …
Phase 2 • Sponsor: BioArctic AB • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Could a biodegradable device help heal spinal cords?
Disease control CompletedThis early-phase trial tested a device called SC0806, which is surgically implanted into the spine. It releases a growth factor to encourage nerve repair in people with complete spinal cord injury. Ten participants were randomly assigned to receive either the device plus rehabili…
Phase 1/2 • Sponsor: BioArctic AB • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC